Work

P86.03 A Phase 2 Study of Erdafitinib in Patients with Advanced Solid Tumors and Fibroblast Growth Factor Receptor Gene Alterations

Year: 2021

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2021.01.1232

Authors: S. Pant, J. Tabernero, C. Massard, D.M. Hyman, O. Witt, T. Doi, S. Qin, C. Lu-Emerson, D. Hargrave, J. Garcia-Corbacho, S. Little, J. Tolbert, A. Santiago-Walker, C. Moy, C. Hammond, Y.Y. Lau, H. Sweiti, M. Schuler

Institutions: The University of Texas MD Anderson Cancer Center, Vall d'Hebron Institute of Oncology, Memorial Sloan Kettering Cancer Center, German Cancer Research Center, Heidelberg University, Hopp Children's Cancer Center Heidelberg, National Cancer Center Hospital East, 81th Hospital of PLA, Tufts University, Great Ormond Street Hospital, University College London, Hospital Clínic de Barcelona, Janssen Research & Development (United States), Essen University Hospital

Language: English

Topic: Fibroblast Growth Factor Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3137683014

Cites:

Cited by:

Related to: 10